Get to know our clinical trials
Clinical trial to evaluate the safety, tolerability and pharmacokinetics of the anti-CCR8 antibody BAY 3375968, in monotherapy and in combination with pembrolizumab, in patients with selected advanced solid tumors.
THE MAIN OBJECTIVE IS TO LEARN WHETHER BAY 3375968 ADMINISTERED ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IS SAFE FOR PARTICIPANTS AND HOW IT AFFECTS THE BODY.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- FIRST-IN-HUMAN, DOSE-ESCALATING, EXTENDED DOSE ESCALATION TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE ANTI-CCR8 ANTIBODY BAY 3375968, IN MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB, IN PATIENTS WITH SELECTED ADVANCED SOLID TUMORS
- Code EudraCT: 2023-505594-32-00
- Protocol number: 21820 /BAY3375968
- Promoter: Bayer Hispania S.L
- Molecule/Drug: BAY3375968
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.